Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

Engineered FGF19ΔKLB protects against intrahepatic cholestatic liver injury in ANIT-induced and Mdr2-/- mice model

Abstract Background The major safety concern of the clinical application of wild type FGF19 (FGF19WT) emerges given that its extended treatment causes hepatocellular carcinoma. Therefore, we previously generated a safer FGF19 variant - FGF19ΔKLB, which have same effects on glycemic control and bile...

Full description

Bibliographic Details
Main Authors: Lu Shi, Tiantian Zhao, Lei Huang, Xiaomin Pan, Tianzhen Wu, Xin Feng, Taoli Chen, Jiamin Wu, Jianlou Niu
Format: Article
Language:English
Published: BMC 2023-10-01
Series:BMC Biotechnology
Subjects:
FGF19
Hepatocellular carcinoma
Bile acids
Intrahepatic cholestasis
Inflammation
Online Access:https://doi.org/10.1186/s12896-023-00810-9

Internet

https://doi.org/10.1186/s12896-023-00810-9

Similar Items